#India #Mumbai #Lupin Limited #ESMO Congress #LNP3693

Lupin Limited's Upcoming Presentation at ESMO Congress 2025

Lupin Limited, a global pharmaceutical powerhouse based in Mumbai, India, has exciting news on the horizon. From October 17 to 21, 2025, the company will present its Phase-1 clinical study results for LNP3693, a promising STING agonist, at the prestigious European Society for Medical Oncology (ESMO) Congress in Berlin. This announcement marks another significant milestone for Lupin in its quest to advance oncology treatments.

Event Overview

The presentation titled "A Phase 1 Dose Escalation Study of LNP3693 (STING Agonist) in Patients with Advanced or Metastatic Solid Tumors and Lymphoma" (Presentation Number 1553P) will take place during a session on Investigational Immunotherapy. Attendees can view this pivotal presentation on October 19, 2025, between 9:00 AM to 5:00 PM CEST.

A Look at LNP3693

LNP3693 is currently in clinical development as a parenteral STING agonist, showcasing a novel mechanism of action aimed at enhancing the body's immune response against cancers. The results shared at the ESMO congress will provide crucial insights into the drug's safety profile, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity observed in patients with various solid tumors.

Vinita Gupta, CEO of Lupin, emphasized the significance of this presentation, stating, "This is a crucial milestone for us. Following our successful presentation of LNP7457, a PRMT5 inhibitor at the ASCO Congress in June 2025, it is an honor to share the outcomes of another Phase-1 study for LNP3693, a STING agonist, at ESMO. The acknowledgment of clinical research conducted in India by ESMO highlights our team's expertise in discovering, researching, and clinically developing cancer therapeutics."

Presentation Details

• - Date and Time: Sunday, October 19, 2025, 9:00 AM – 5:00 PM (CEST)
• - Session Title: A Phase 1 Dose Escalation Study of LNP3693 (STING Agonist) in Patients with Advanced or Metastatic Solid Tumors and Lymphoma
• - Session Category: Investigational Immunotherapy
• - Clinical Trial Registration Number: CTRI/2023/10/059147
• - Presentation Number: 1553P

In addition to the live presentation, all accepted abstracts for the ESMO Congress 2025 will be available online, including those submitted for this significant study. These abstracts will also be featured in the ESMO Congress 2025 Abstract Book, which accompanies the official ESMO journal, Annals of Oncology.

About Lupin Limited

Lupin Limited has established itself as a leading global player in the pharmaceutical industry. Known for its extensive portfolio that includes both branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients, Lupin's drugs are distributed across more than 100 markets worldwide. The company enjoys a strong reputation among healthcare professionals and patients alike, particularly in the areas of respiratory illness, cardiovascular health, diabetes, infectious diseases, gastrointestinal disorders, central nervous system disorders, and women's health.

With a workforce of 24,000 employees, Lupin operates 15 modern manufacturing facilities and 7 research centers globally. The company is also committed to improving patient health through its subsidiaries, including Lupin Diagnostics, Lupin Digital Health, and Lupin Manufacturing Solutions.

For more information on Lupin and their initiatives, visit www.lupin.com or follow them on LinkedIn.

Conclusion

As the ESMO Congress 2025 approaches, the anticipation surrounding Lupin's presentation of LNP3693's Phase-1 data continues to grow. This could mark a significant leap forward in immunotherapy for patients battling advanced cancers, reflecting Lupin's ongoing commitment to innovative therapies that enhance patient outcomes.